Submitted by jup2017 on November 13, 2017 - 3:04pm
| Title | Epigenetic therapy leaps ahead with specific targeting of EZH2. |
| Publication Type | Journal Article |
| Year of Publication | 2012 |
| Authors | Melnick, Ari |
| Journal | Cancer Cell |
| Volume | 22 |
| Issue | 5 |
| Pagination | 569-70 |
| Date Published | 2012 Nov 13 |
| ISSN | 1878-3686 |
| Abstract | <p>The Polycomb epigenetic silencing protein EZH2 is affected by gain-of-function somatic mutations in B cell lymphomas. Two recent reports describe the development of highly selective EZH2 inhibitors and reveal mutant EZH2 as playing an essential role in maintaining lymphoma proliferation. EZH2 inhibitors are thus a promising new targeted therapy for lymphoma.</p> |
| DOI | 10.1016/j.ccr.2012.10.016 |
| Alternate Journal | Cancer Cell |
| PubMed ID | 23153531 |
| PubMed Central ID | PMC3732786 |
| Grant List | R01 CA104348 / CA / NCI NIH HHS / United States R01 CA143032 / CA / NCI NIH HHS / United States |